Pelvic and pulmonary benign metastasizing leiomyoma: A case report
Publication date: Available online 31 March 2018 Source:Case Reports in Women's Health Author(s): Jennifer B. Bakkensen, Wesley Samore, Pietro Bortoletto, Cynthia C. Morton, Raymond M. Anchan Seven years after she had a total abdominal hysterectomy for benign leiomyomas, a 46-year-old woman presented with a pelvic mass and multiple pulmonary nodules. She underwent resection of the mass and core needle biopsy of a pulmonary lesion. Histopathologic analysis revealed that both the pelvic and the pulmonary lesions were consistent with benign leiomyomas. Benign metastasizing leiomyoma should be considered if a woman of reproductive age and with a history of leiomyomas presents with extrauterine nodules without evidence of malignancy. The final diagnosis should be based on histopathological examination. Treatment depends on tumor size, location, receptor positivity, and disease progression.
This article reports on a case of myomectomy of subserous leiomyoma that was causing septic necrosis, leukocytosis, rise of inflammatory markers (erythrocyte sedimentation rate and C-reactive protein), and pressure symptom on the liver. Myomectomy was performed at 20 weeks of gestation. The pregnancy continued with no further problems, and at 39 weeks and 1 day of gestation, vaginal delivery resulted in a healthy baby. It is postulated that when myomectomy is performed in carefully selected patients, it prevents sepsis due to myoma torsion and necrosis and also protects surrounding organs against damage. PMID: 31673533 [PubMed]
(Abstracted from Obstet Gynecol 2019;134:261–269) One or more leiomyomas will be detected by abdominal or pelvic imaging by age 50 years in 70% of white women and more than 80% of African American women. Most leiomyomas are asymptomatic, but 25% to 30% of affected women will experience pelvic pain, heavy or prolonged menstrual bleeding, bulk symptoms (ie, pelvic pressure or genitourinary symptoms), and/or reproductive dysfunction.
Conclusion and Relevance Clinical implications of these associations are 2-fold. First, screening and early modification of CMRFs can be part of a preventive strategy for uterine leiomyomas and hysterectomy. Second, patients diagnosed with uterine leiomyomas or endometriosis can be screened and closely followed for CMRFs and cardiovascular disease. Target Audience Obstetricians and gynecologists, family physicians. Learning Objectives After participating in this activity, the learner should be better able to identify the association between cardiometabolic risk factors and benign gynecologic disorders; explain the ...
Uterine leiomyomas (fibroids) represent the most common benign pelvic tumors in women as well as the leading indication for hysterectomies in the United States. Risk factors for the development of fibroids include increasing age, hormonal changes, genetics, and race, among others. The lifetime risk of developing fibroids is greater than 80% among African American women, who also have the more severe form of this condition. We are presenting a case of incidental 18F-NaF uptake in the calcified uterine leiomyoma of a 52-year-old African American woman.
ConclusionThe Robotic Single-Site hysterectomy is a safe, reliable and feasible surgical method in gynecology.
ConclusionThe da Vinci SP surgical system enables easy rotation of camera and instruments at once and this make it easy to perform the procedures which are performed above the umbilicus for the huge uterine leiomyoma reaching the diaphragm.
We describe the management of this condition and discuss about parasitic leiomyoma together with a review of the literature.
To describe the experience of robotic-assisted single port supracervical hysterectomy with bilateral salpingectomy on a giant uterine leiomyoma using the da Vinci SP surgical system.
A middle-aged woman presented with a large pelvic mass of uncertain origin. Intraoperatively, the mass was found to be contiguous with the uterus. The patient underwent hysterectomy and was found to have a large, pedunculated, multilobulated leiomyoma with degenerative change.
Directive clinique No 389 - Prise en charge médicamenteuse des léiomyomes utérins symptomatiques - Addenda. J Obstet Gynaecol Can. 2019 Oct;41(10):1525-1528 Authors: Laberge PY, Murji A, Vilos GA, Allaire C, Leyland N, Sony S Abstract OBJECTIFS: Les directives du présent addenda visent à fournir aux cliniciens une mise à jour de la directive clinique de 2015 sur la prise en charge des fibromes utérins. Comme de nouveaux renseignements et de nouvelles données probantes ont vu le jour depuis 2015, le comité de pratique clinique - gyn&eac...